A recent study from the PIONEER REAL Netherlands trial demonstrated that oral semaglutide effectively manages type 2 diabetes and supports weight loss in adults.
By Dr. Sanchari Sinha Dutta, Ph.D.Reviewed by Benedette Cuffari, M.Sc.Jun 18 2024 A recent study published in the journal Diabetes Therapy discusses the results of the PIONEER REAL study conducted in the Netherlands, which evaluated the efficacy of oral semaglutide in managing type 2 diabetes and supporting weight loss .
The Netherlands Diabetes Federation recommends a stepwise introduction of diabetes treatments based on glycated hemoglobin levels. Typically, treatment is initiated sequentially with metformin and sulphonylureas, followed by the incorporation of insulin, glucagon-like peptide-1 receptor agonists , or dipeptidyl peptidase-4 inhibitors.
Related StoriesThe primary study endpoint was to assess changes in HbA1c levels from baseline to the end of the study, whereas secondary endpoints included changes in body weight. The study participants were also provided with a questionnaire-based assessment of treatment satisfaction. About 98% of participants received three milligrams of oral semaglutide, whereas 2% received seven mg of oral semaglutide for a median duration of 37.7 weeks.
Semaglutide Type 2 Diabetes Efficacy Glucose Hba1c Insulin Weight Loss
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Real Madrid vs Real Betis: Primera DivisiónFollow live text commentary, score updates and match stats from Real Madrid vs Real Betis in the Primera División
Weiterlesen »
Hospitals' cyber-attack: Why a task force is needed to halt a sophisticated enemy: Greg WrightCyber attacks cause real harm to real people.
Weiterlesen »
Green Party says it’s ‘on the up’ as it launches General Election campaignCo-leader Adrian Ramsay said the party is offering ‘real hope and real change’ to voters.
Weiterlesen »
Green Party says it’s ‘on the up’ as it launches General Election campaignCo-leader Adrian Ramsay said the party is offering ‘real hope and real change’ to voters.
Weiterlesen »
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophyThe U.S. Food and Drug Administration has approved the first generic version of Emflaza (deflazacort) oral suspension for Duchenne muscular dystrophy (DMD). Approval of the generic version of Emflaza oral suspension was granted to Cranbury Pharmaceuticals (Tris Pharma).
Weiterlesen »
Increasing use and awareness of oral nicotine pouches detailedA rigorous, comprehensive synthesis of evidence from 62 studies related to the use of oral nicotine pouches by Georgetown University's Lombardi Comprehensive Cancer Center scientists and colleagues provides a much-needed assessment of how these products could lead to potential harmful consequences if used by young people.
Weiterlesen »